Arkolith/Insider Trading/CTIC/Form 4

Kirske David

EVP, Chief Financial OfficerCTI BIOPHARMA CORP (CTIC) · full profile →Form 4 · filed Jun 26, 2023
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
9
1 non-derivative · 8 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Jun 26, 2023Tender(U)18K$9.10$160K0

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Jun 26, 2023Disposed to issuer(D)315K——0
Jun 26, 2023Disposed to issuer(D)83K——0
Jun 26, 2023Disposed to issuer(D)270K——0
Jun 26, 2023Disposed to issuer(D)340K——0
Jun 26, 2023Disposed to issuer(D)150K——0
Jun 26, 2023Disposed to issuer(D)280K——0
Jun 26, 2023Disposed to issuer(D)200K——0
Jun 26, 2023Disposed to issuer(D)25K——0

Transaction Codes

U
See SEC Form 4 code table
D
Disposition to the issuer

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0000899243-23-016485) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML